Fintel reports that on December 9, 2025, B of A Securities maintained coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a Buy recommendation. Analyst Price Forecast Suggests 5.02% Upside As of ...

AstraZeneca's fair value estimate has nudged up to about $150.26 from roughly $146.44, even as the long run revenue growth ...

BofA analyst Jason Gerberry raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $97 from $86 and keeps a Buy rating on the shares ...

Additionally, NDC-011, a novel drug combination developed through DR.NOAH's AI-based drug discovery platform, received Orphan Drug Designation (ODD) from the U.S. FDA in 2023 and IND approval for a ...

Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and trades.

This article has been revised and clarified. Pasadena-based biopharma company Arrowhead Pharmaceuticals Inc. had a ...

Researchers assessed whether a set dose of luspatercept could be safe in treating pediatric patients with non–transfusion dependent beta-thalassemia.

According to DelveInsight's analysis, the acute on chronic liver failure market is anticipated to increase during the forecast period (2025--2034), owing to the launch of emerging therapies such as ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is among the hidden multibagger stocks to invest in. It reported positive results from the registrational cohort of the EMBOLD study 4.

New clinical data presented this week indicates that Sapablursen, an experimental therapy for polycythemia vera (PV), has achieved positive interim results in a Phase 2a study. The findings were ...

The addition of well-respected biotech expert strengthens one of Oppenheimer's longest-standing franchise areasNEW YORK, Dec. 8, 2025 /PRNewswire/ -- ...